Modulating T-cell immunity to tumours: New strategies for monitoring T-cell responses

Nature Reviews Cancer

Volumn 2, Issue 6, 2002, Pages 409-419

  Yee, Cassian ^a,b   Greenberg, Philip ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; VACCINE;

ANIMAL; CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; REVIEW; T LYMPHOCYTE; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ASSAY; EFFECTOR CELL; FLOW CYTOMETRY; IMMUNOLOGICAL MONITORING; IMMUNOREGULATION; INHIBITION KINETICS; INTERMETHOD COMPARISON; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CLINICAL TRIALS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 0036593490     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc820     Document Type: Review

References (107)

1. van den Eynde, B. J. #38; van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684-693 (1997).
2. Mitchell, M. S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 25, 623-635 (1998).
3. Hsueh, E. C. et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with intransit melanoma metastases. Cancer 85, 2160-2169 (1999).
4. Musselli, C., Livingston, P. O. #38; Ragupathi, G. Keyhole limpet hemocyanin conjugate vaccines against cancer: The Memorial Sloan-Kettering experience. J. Cancer Res. Clin. Oncol. 127 (Suppl. 2), R20-R26 (2001).
5. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).
6. +cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc. Natl Acad. Sci. USA 93, 10399-10404 (1996).
7. Simons, J. W. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546 (1997).
8. 1-biasing cytokines IL-12 and IFN-α. J. Immunol. 160, 1139-1147 (1998).
9. Kwak, L. W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209-1215 (1992).
10. Boczkowski, D., Nair, S. K., Snyder, D. #38; Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
11. Larregina, A. T. et al. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther. 8, 608-617 (2001).
12. Reichardt, V. L. et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 93, 2411-2419 (1999).
13. Reddy, S. A., Okada, C., Wong, C., Bahler, D. #38; Levy, R. T cell antigen receptor vaccines for active therapy of T cell malignancies. Ann. NY Acad. Sci. 941, 97-105 (2001).
14. Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
15. Fong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98, 8809-8814 (2001). In a clinical trial using dendritic cells pulsed with an altered peptide ligand of CEA to vaccinate patients with colon cancer, the authors show, using tetramer analysis, that expansion of CEA-specific T cells in vivo correlated with clinical responses.
16. Thurner, B. et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678 (1999). Regression of individual lesions were observed in 6 out of 11 patients with advanced melanoma receiving a MAGE3-pulsed dendritic-cell vaccine. Antigen-loss variants were identified in residual tumour of some patients.
17. Rosenberg, S. A., Spiess, P. #38; Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321 (1986).
18. +HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum. Gene Ther. 3, 319-338 (1992).
19. Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644 (2000). In a patient receiving adoptive therapy with T-cell clones targeting MART1, transferred T cells were tracked with peptide-MHC tetramers and shown to migrate to antigen-positive sites of skin and tumour and to mediate an antigen-specific immune response.
20. Yee, C., Riddell, S. R. #38; Greenberg, P. D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9, 702-708 (1997).
21. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M. #38; Greenberg, P. D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 2227-2234 (1999). Peptide-MHC tetramers were used to define the TCR affinity of antigen-specific T cells (see also reference 87).
22. Simon, R. M. et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 19, 1848-1854 (2001).
23. Disis, M. L. et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6, 1347-1350 (2000).
24. Habal, N. et al. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann. Surg. Oncol. 8, 389-401 (2001).
25. Hsueh, E. C., Gupta, R. K., Qi, K. #38; Morton, D. L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 16, 2913-2920 (1998).
26. Lee, P. et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847 (2001).
27. Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1996).
28. Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171-1177 (1999).
29. Marchand, M. et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE3. Int. J. Cancer 63, 883-885 (1995).
30. Marchand, M. et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80, 219-230 (1999).
31. Mukherji, B. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl Acad. Sci. USA 92, 8078-8082 (1995).
32. Cormier, J. N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from Mart1/Melan A. Cancer J. Sci. Am. 3, 37-44 (1997).
33. Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
34. Jager, E. et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA 97, 4760-4765 (2000). References 26-34 describe some of the clinical trials that involve augmentation of an antigen-specific T-cell response.
35. Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
36. Davis, M. M. et al. T cell receptor biochemistry, repertoire selection and general features of TCR and Ig structure. Ciba Found. Symp. 204, 94-100; discussion 100-104 (1997).
37. Schneck, J. P. Monitoring antigen-specific T cells using MHC-Ig dimers. Immunol. Invest. 29, 163-169 (2000).
38. Yee, C., Davis, M. M. #38; Lee, P. P. The Use of Peptide-MHC Tetramers in T-Cell Therapy of Melanoma (Academic Press, San Diego, 2000).
39. Lee, P. P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med. 5, 677-685 (1999). Multiparametric analysis of endogenous populations of circulating tumour-specific T cells revealed an activational defect in T cells that recognize melanoma-associated differentiation antigens.
40. +T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).
41. Haanen, J. et al. In situ detection of virus- and tumor-specific T-cell immunity. Nature Med. 6, 1056-1060 (2000).
42. Lee, K. H. et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 161, 4183-4194 (1998).
43. Pongers-Willemse, M. J. et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12, 2006-2014 (1998).
44. Coulie, P. G. et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl Acad. Sci. USA 98, 10290-10295 (2001).
45. Riddell, S. R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2, 216-223 (1996).
46. Thomis, D. C. et al. A FAS-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97, 1249-1257 (2001).
47. Brodie, S. J. et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med. 5, 34-41 (1999). In situ localization of gene-marked T-cell clones in situ following adoptive T-cell therapy.
48. Lamana, M. L., Segovia, J. C., Guenechea, G. #38; Bueren, J. A. Systematic analysis of clinically applicable conditions leading to a high efficiency of transduction and transgene expression in human T cells. J. Gene Med. 3, 32-41 (2001).
49. Kammula, U. S. et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163, 6867-6875 (1999). Application of real-time PCR analysis of cytokine expression to evaluate antigen-specific T-cell response to vaccination.
50. Mocellin, S., Ohnmacht, G. A., Wang, E. #38; Marincola, F. M. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int. J. Cancer 93, 236-242 (2001).
51. Pala, P., Hussell, T. #38; Openshaw, P. J. M. Flow cytometric measurement of intracellular cytokines. J. Immunol. Methods 243, 107-124 (2000).
52. Murali-Krishna, K. et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177-187 (1998).
53. Becker, C. et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nature Med. 7, 1159-1162 (2001).
54. +T lymphocytes secreting tumor necrosis factor-α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods 191, 131-142 (1996).
55. Grijatic, S. et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl Acad. Sci. USA 97, 10917-10922 (2000).
56. +T lymphocytes producing tumor necrosis factor-α spots in response to peptide antigens. J. Immunol. Methods 203, 141-152 (1997).
57. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med 188, 2205-2213 (1998).
58. Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single-hit Poisson model. J. Immunol. Methods 72, 29-40 (1984).
59. +cancers. Proc. Natl Acad. Sci. USA 97, 12198-12203 (2000). Stabilization and regression of individual metastases in some patients with melanoma, receiving a peptide vaccine that targets NY-ESO-1, provide evidence of clinical correlation with ELISPOT analyses.
60. Molldrem, J. J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Med. 6, 1018-1023 (2000).
61. Lee, K. H. et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292-6300 (1999).
62. Fong, L. et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 167, 7150-7156 (2001).
63. Cheever, M. A., Thompson, D. B., Klarnet, J. P. #38; Greenberg, P. D. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. Exp. Med. 163, 1100-1112 (1986).
64. +T cells or CTL immunotherapy of tumors expressing the antigen J. Immunol. 166, 2863-2870 (2001).
65. Ochsenbein, A. F. et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl Acad. Sci. USA 96, 2233-2238 (1999).
66. Mihm, M. C. Jr, Clemente, C. G. #38; Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74, 43-47 (1996).
67. Underwood, J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br. J. Cancer 30, 538-548 (1974).
68. Watt, A. G. #38; House, A. K. Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer 41, 279-282.
69. van Nagell, J. R. Jr, Donaldson, E. S. Wood, E. G. #38; Parker, J. C. Jr. The significance of vascular invasion and lymphocytic infiltration in invasive cervical cancer. Cancer 41, 228-234 (1978).
70. +T cell adoptive immunotherapy. Immunity 13, 265-276 (2000).
71. Speiser, D. E. #38; Ohashi, P. S. Activation of cytotoxic T cells by solid tumours? Cell. Mol. Life Sci. 54, 263-271 (1998).
72. Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
73. Hardy, J. et al. Bioluminescence imaging of lymphocyte trafficking in vivo. Exp. Hematol. 29, 1353-1360 (2001).
74. Mizoguchi, H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798 (1992).
75. Correa, M. R. et al. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158, 5292-5296 (1997).
76. +T cell responses. Nature Immunol. 3, 189-195 (2002).
77. +T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol. 163, 102-110 (1999).
78. Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95, 1178-1183 (1998).
79. Torre-Amione, G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type-B1 cDNA escapes immune surveillance. Proc. Natl Acad. Sci. USA 87, 1486-1490 (1990).
80. +T cells.
81. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. #38; Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl Acad. Sci. USA 93, 7855-7860 (1996).
82. Alexander-Miller, M. A., Leggatt, G. R. #38; Berzofsky, J. A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93, 4102-4107 (1996).
83. Gervois, N., Guilloux, Y., Diez, E. #38; Jotereau, F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183, 2403-2407 (1996).
84. Crawford, F., Kozono, H., White, J., Marrack, P. #38; Kappler, J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8, 675-682 (1998).
85. Savage, P. A., Boniface, J. J. #38; Davis, M. M. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10, 485-492 (1999).
86. Noppen, C., Spagnoli, G. C. #38; Schaefer, C, Isolation of multiple mRNAs from a few eukaryotic cells: a fast method to obtain templates for RT-PCR. Biotechniques 21, 394-396 (1996).
87. Dutoit, V. et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168, 1167-1171 (2002). Peptide-MHC tetramers were used to define the TCR affinity of antigen-specific T cells (see also reference 21).
88. Kessels, H. W., Wolkers, M. C., van den Boom, M. D., van der Valk, M. A. #38; Schumacher, T. N. Immunotherapy through TCR gene transfer. Nature Immunol. 2, 957-961 (2001). Designing T cells with a given antigen specificity by the transfer of genes that encode the TCR.
89. Urban, J. L., Holland, J. M., Kripke, M. L. Schreider H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J. Exp. Med. 156, 1025-1041 (1982).
90. Saleh, F. H., Crotty, K. A., Hersey, P. #38; Menzies, S. W. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen Melan-A/MART-1. Int. J. Cancer 94, 551-557 (2001).
91. Shankaran, V. et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001). Endogenous immunoselection of tumour cells can lead to the appearance of antigen-loss tumour variants that escape immune detection in the immunocompetent host.
92. Panelli, M. C. et al. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J. Immunol. 164, 495-504 (2000).
93. Vitale, M. et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 58, 737-742 (1998).
94. Ferrone, S. #38; Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487-494 (1995).
95. Hicklin, D. J., Kageshita, T. #38; Ferrone, S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens 48, 38-46 (1996).
96. Wang, Z., Margulies, L., Hicklin, D. J. #38; Ferrone, S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 47, 382-390 (1996).
97. Yang, G., Hellstrom, K. E., Mizuno, M. T. #38; Chen, L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol. 155, 3897-3903 (1995).
98. Beck, C., Schreiber, H. #38; Rowley, D. Role of TGF-β in immune-evasion of cancer. Microsc. Res. Tech. 52, 387-395 (2001).
99. Barth, R. J. Jr, Camp, B. J., Martuscello, T. A., Dain, B. J. #38; Memoli, V.A. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-α and interleukin-4 predicts improved survival. Cancer 78, 1168-1178 (1996).
100. Zea, A. H. et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1, 1327-1335 (1995).
101. Maccalli, C. et al. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions J. Immunol. 163, 6912-6923 (1999).
102. Bladergroen, B. A. et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99, 232-237 (2002).
103. Medema, J. P., de Jong, J., van Hall, T, Melief, C. J. #38; Offringa, R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190, 1033-1038 (1999).
104. Ambrosini, G., Adida, C. #38; Altieri, D.C. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917-921 (1997).
105. Nakashima, M., Sonoda, K. #38; Watanabe, T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nature Med. 5, 938-942 (1999).
106. Mellado, M., de Ana, A. M., Moreno, M. C., Martinez, C. #38; Rodriguez-Frade, J. M. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr. Biol. 11, 691-696 (2001).
107. Riker, A. I. et al. Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. Cancer Detect. Prev. 23, 387-396 (1999). References 93-107 describe mechanisms of tumour immune escape through defects in antigen expression or antigen presentation (references 93-96), the presence of an immune-suppressive tumour microenvironment (references 97-101) and tumour upregulation of immunoprotective mechanisms (references 101-107).